Compugen Ltd. (NASDAQ:CGEN) Receives Average Rating of “Buy” from Analysts

Shares of Compugen Ltd. (NASDAQ:CGEN) have earned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $5.00.

A number of research analysts have commented on the company. Wall Street Zen downgraded Compugen from a “buy” rating to a “hold” rating in a research note on Saturday, May 23rd. HC Wainwright reaffirmed a “buy” rating on shares of Compugen in a research note on Tuesday, August 4th. Leerink Partners reduced their price target on Compugen from $13.00 to $5.00 and set an “outperform” rating for the company in a report on Thursday, May 21st. Finally, Weiss Ratings raised shares of Compugen from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Wednesday, August 5th.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC raised its holdings in shares of Compugen by 12.1% during the 1st quarter. Renaissance Technologies LLC now owns 1,632,988 shares of the biotechnology company’s stock valued at $3,478,000 after purchasing an additional 176,088 shares in the last quarter. State Street Corp boosted its holdings in Compugen by 3.9% in the fourth quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after purchasing an additional 14,701 shares in the last quarter. Jane Street Group LLC boosted its holdings in Compugen by 1,077.0% in the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock worth $700,000 after purchasing an additional 359,785 shares in the last quarter. Two Sigma Investments LP increased its position in Compugen by 10.6% during the third quarter. Two Sigma Investments LP now owns 197,875 shares of the biotechnology company’s stock worth $291,000 after buying an additional 18,929 shares during the last quarter. Finally, Marshall Wace LLP increased its position in Compugen by 135.7% during the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock worth $163,000 after buying an additional 61,202 shares during the last quarter. Institutional investors and hedge funds own 12.22% of the company’s stock.

Compugen Stock Down 5.8%

Shares of NASDAQ:CGEN opened at $2.60 on Friday. The firm has a fifty day moving average of $2.36 and a two-hundred day moving average of $2.33. Compugen has a 12-month low of $1.29 and a 12-month high of $3.23. The firm has a market capitalization of $245.83 million, a P/E ratio of 6.84 and a beta of 2.77.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Monday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. Compugen had a net margin of 47.56% and a return on equity of 42.57%. The business had revenue of $2.60 million for the quarter, compared to the consensus estimate of $1.28 million. During the same period in the prior year, the business posted ($0.08) earnings per share. Equities research analysts expect that Compugen will post -0.27 earnings per share for the current fiscal year.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.